169 related articles for article (PubMed ID: 22074378)
1. A predictive biomimetic model of cytokine release induced by TGN1412 and other therapeutic monoclonal antibodies.
Dhir V; Fort M; Mahmood A; Higbee R; Warren W; Narayanan P; Wittman V
J Immunotoxicol; 2012; 9(1):34-42. PubMed ID: 22074378
[TBL] [Abstract][Full Text] [Related]
2. Endothelial cells co-stimulate peripheral blood mononuclear cell responses to monoclonal antibody TGN1412 in culture.
Findlay L; Sharp G; Fox B; Ball C; Robinson CJ; Bird C; Stebbings R; Eastwood D; Wadhwa M; Poole S; Thorpe R; Thorpe SJ
Cytokine; 2011 Jul; 55(1):141-51. PubMed ID: 21493088
[TBL] [Abstract][Full Text] [Related]
3. A whole blood in vitro cytokine release assay with aqueous monoclonal antibody presentation for the prediction of therapeutic protein induced cytokine release syndrome in humans.
Wolf B; Morgan H; Krieg J; Gani Z; Milicov A; Warncke M; Brennan F; Jones S; Sims J; Kiessling A
Cytokine; 2012 Dec; 60(3):828-37. PubMed ID: 22986013
[TBL] [Abstract][Full Text] [Related]
4. Antibody C region influences TGN1412-like functional activity in vitro.
Ball C; Fox B; Hufton S; Sharp G; Poole S; Stebbings R; Eastwood D; Findlay L; Parren PW; Thorpe R; Bristow A; Thorpe SJ
J Immunol; 2012 Dec; 189(12):5831-40. PubMed ID: 23150712
[TBL] [Abstract][Full Text] [Related]
5. A simple whole blood bioassay detects cytokine responses to anti-CD28SA and anti-CD52 antibodies.
Bailey L; Moreno L; Manigold T; Krasniqi S; Kropshofer H; Hinton H; Singer T; Suter L; Hansel TT; Mitchell JA
J Pharmacol Toxicol Methods; 2013; 68(2):231-239. PubMed ID: 23280407
[TBL] [Abstract][Full Text] [Related]
6. Cytokine release assays for the prediction of therapeutic mAb safety in first-in man trials--Whole blood cytokine release assays are poorly predictive for TGN1412 cytokine storm.
Vessillier S; Eastwood D; Fox B; Sathish J; Sethu S; Dougall T; Thorpe SJ; Thorpe R; Stebbings R
J Immunol Methods; 2015 Sep; 424():43-52. PubMed ID: 25960173
[TBL] [Abstract][Full Text] [Related]
7. Is an in vitro whole blood cytokine assay useful to detect the potential risk of severe infusion reaction of monoclonal antibody pharmaceuticals?
Iwata Y; Harada A; Hara T; Kubo C; Inoue T; Tabo M; Ploix C; Manigold T; Hinton H; Mishima M
J Toxicol Sci; 2016; 41(4):523-31. PubMed ID: 27432238
[TBL] [Abstract][Full Text] [Related]
8. An autologous endothelial cell:peripheral blood mononuclear cell assay that detects cytokine storm responses to biologics.
Reed DM; Paschalaki KE; Starke RD; Mohamed NA; Sharp G; Fox B; Eastwood D; Bristow A; Ball C; Vessillier S; Hansel TT; Thorpe SJ; Randi AM; Stebbings R; Mitchell JA
FASEB J; 2015 Jun; 29(6):2595-602. PubMed ID: 25746794
[TBL] [Abstract][Full Text] [Related]
9. Development of a human whole blood assay for prediction of cytokine release similar to anti-CD28 superagonists using multiplex cytokine and hierarchical cluster analysis.
Walker MR; Makropoulos DA; Achuthanandam R; Van Arsdell S; Bugelski PJ
Int Immunopharmacol; 2011 Nov; 11(11):1697-705. PubMed ID: 21689786
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of a TGN1412 analogue using in vitro assays and two immune humanized mouse models.
Yan H; Bhagwat B; Sanden D; Willingham A; Tan A; Knapton AD; Weaver JL; Howard KE
Toxicol Appl Pharmacol; 2019 Jun; 372():57-69. PubMed ID: 30914376
[TBL] [Abstract][Full Text] [Related]
11. Comparison of novel methods for predicting the risk of pro-inflammatory clinical infusion reactions during monoclonal antibody therapy.
Findlay L; Eastwood D; Ball C; Robinson CJ; Bird C; Wadhwa M; Thorpe SJ; Thorpe R; Stebbings R; Poole S
J Immunol Methods; 2011 Aug; 371(1-2):134-42. PubMed ID: 21741383
[TBL] [Abstract][Full Text] [Related]
12. "Cytokine storm" in the phase I trial of monoclonal antibody TGN1412: better understanding the causes to improve preclinical testing of immunotherapeutics.
Stebbings R; Findlay L; Edwards C; Eastwood D; Bird C; North D; Mistry Y; Dilger P; Liefooghe E; Cludts I; Fox B; Tarrant G; Robinson J; Meager T; Dolman C; Thorpe SJ; Bristow A; Wadhwa M; Thorpe R; Poole S
J Immunol; 2007 Sep; 179(5):3325-31. PubMed ID: 17709549
[TBL] [Abstract][Full Text] [Related]
13. After TGN1412: recent developments in cytokine release assays.
Stebbings R; Eastwood D; Poole S; Thorpe R
J Immunotoxicol; 2013; 10(1):75-82. PubMed ID: 22967038
[TBL] [Abstract][Full Text] [Related]
14. Human regulatory T cells are selectively activated by low-dose application of the CD28 superagonist TGN1412/TAB08.
Tabares P; Berr S; Römer PS; Chuvpilo S; Matskevich AA; Tyrsin D; Fedotov Y; Einsele H; Tony HP; Hünig T
Eur J Immunol; 2014 Apr; 44(4):1225-36. PubMed ID: 24374661
[TBL] [Abstract][Full Text] [Related]
15. Development of the first reference antibody panel for qualification and validation of cytokine release assay platforms - Report of an international collaborative study.
Vessillier S; Fort M; O'Donnell L; Hinton H; Nadwodny K; Piccotti J; Rigsby P; Staflin K; Stebbings R; Mekala D; Willingham A; Wolf B;
Cytokine X; 2020 Dec; 2(4):100042. PubMed ID: 33458650
[TBL] [Abstract][Full Text] [Related]
16. Monoclonal antibody TGN1412 trial failure explained by species differences in CD28 expression on CD4+ effector memory T-cells.
Eastwood D; Findlay L; Poole S; Bird C; Wadhwa M; Moore M; Burns C; Thorpe R; Stebbings R
Br J Pharmacol; 2010 Oct; 161(3):512-26. PubMed ID: 20880392
[TBL] [Abstract][Full Text] [Related]
17. Different players generate positive responses in two in vitro cytokine assay formats with aqueous and immobilized TGN1412 analog.
Iwata Y; Harada A; Kubo C; Inoue T; Tabo M; Mishima M
Biochem Biophys Res Commun; 2018 Jul; 502(1):91-97. PubMed ID: 29787754
[TBL] [Abstract][Full Text] [Related]
18. Extracorporeal human whole blood in motion, as a tool to predict first-infusion reactions and mechanism-of-action of immunotherapeutics.
Fletcher EAK; Eltahir M; Lindqvist F; Rieth J; Törnqvist G; Leja-Jarblad J; Mangsbo SM
Int Immunopharmacol; 2018 Jan; 54():1-11. PubMed ID: 29100032
[TBL] [Abstract][Full Text] [Related]
19. TGN1412 Induces Lymphopenia and Human Cytokine Release in a Humanized Mouse Model.
Weißmüller S; Kronhart S; Kreuz D; Schnierle B; Kalinke U; Kirberg J; Hanschmann KM; Waibler Z
PLoS One; 2016; 11(3):e0149093. PubMed ID: 26959227
[TBL] [Abstract][Full Text] [Related]
20. Improved in vitro methods to predict the in vivo toxicity in man of therapeutic monoclonal antibodies including TGN1412.
Findlay L; Eastwood D; Stebbings R; Sharp G; Mistry Y; Ball C; Hood J; Thorpe R; Poole S
J Immunol Methods; 2010 Jan; 352(1-2):1-12. PubMed ID: 19895813
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
